Valneva SE

French biotechnology company

Valneva SE

Type	Public
Key people	Thomas Lingelbach (CEO)
Industry	Biotechnology
Products	Vaccines
Website	[valneva.com Official website]

Valneva SE is a French biotechnology company that specializes in the development and commercialization of vaccines for infectious diseases. The company was formed in 2013 through the merger of Vivalis SA and Intercell AG. Valneva is headquartered in Saint-Herblain, France.

History

Valneva was established in 2013 following the merger of two European biotechnology companies, Vivalis SA from France and Intercell AG from Austria. The merger aimed to create a leading company in the field of vaccines, leveraging the strengths of both companies in research and development.

Products

Valneva focuses on developing vaccines for infectious diseases with significant unmet medical needs. Some of the key products in Valneva's portfolio include:

• IXIARO: A vaccine for the prevention of Japanese encephalitis, a disease prevalent in Asia.
• DUKORAL: An oral vaccine for the prevention of cholera and traveler's diarrhea caused by Escherichia coli.
• VLA2001: A vaccine candidate for COVID-19, which is based on an inactivated virus platform.

Research and Development

Valneva invests heavily in research and development to expand its vaccine portfolio. The company collaborates with various organizations and governments to advance its vaccine candidates through clinical trials. Valneva's R&D efforts are focused on diseases such as Lyme disease, chikungunya, and Zika virus.

Collaborations and Partnerships

Valneva has established several partnerships to enhance its research capabilities and market reach. Notable collaborations include agreements with the U.S. Department of Defense for the development of a chikungunya vaccine and with Pfizer for the development of a Lyme disease vaccine.

Financial Performance

Valneva is publicly traded on the Euronext stock exchange. The company has experienced growth in revenue due to the successful commercialization of its vaccines and strategic partnerships.

Related pages

• Biotechnology
• Vaccine
• Pharmaceutical industry